Auroxyl Capital is a private, fully automated quantitative trading operation on U.S. equities and ETFs. One codebase runs everything: daily data pipeline, factor computation, portfolio construction, risk overlays, and order execution through Interactive Brokers — with no discretionary intervention.
Buys large and mid-cap industry leaders whose momentum survives after stripping out market beta — the stock's own strength, not the market's. Quality confirms the move.
Buys the intersection of cheap and good: earnings/book yield crossed with durable margins and returns on capital — then interrogates whether the cheapness is credible.
The flagship book: AUX-MOM and AUX-VALUE blended by risk parity, then tilted by a momentum-regime probability model — leaning into whichever engine the market currently pays.
The ballast: a CPPI-floored all-weather book across Treasuries, commodities, gold, the dollar and an equity engine — built to compound quietly and cap drawdowns in the single digits.
The edge is not a secret signal — it is a research process that kills bad ideas faster than the market can punish them.
Literature-anchored factors. Every factor is a construction with a known economic mechanism and a decades-long public record — momentum, value, quality, issuance. Sign known before testing; no mined interactions.
Validation before deployment. Shuffle-null tests, walk-forward folds, multi-offset entry perturbation, parameter-flatness checks. Over 90% of researched ideas fail and are archived, not retried until they pass.
Hold, don't fiddle. Exit research converged on a hard result: no stop-loss or ML exit policy beat holding to the rebalance date. The system trades on schedule, not on emotion — because it has no emotions.
Risk lives at the portfolio layer. Entry gates and exit rules failed every test; volatility-complex overlays and regime weighting passed. Risk is managed where the statistics say it can be — above the stock picks, not inside them.
Honest expectations. Live performance is internally budgeted conservatively against research results — expectations are set below what the numbers show, never above.
Taocheng designed and built the entire Auroxyl platform from the ground up — from the daily data pipeline and alpha factor research to the C#/.NET execution engine and IBKR integration. Every component, from data ingestion to order routing, is his work.
His background in data science provides the quantitative foundation for the system's statistical approach: walk-forward validation, bootstrap significance testing, and rigorous overfitting diagnostics are core to the research process.
Daily pipeline over Polygon market + fundamentals data; point-in-time factor panels; full research harness with parity-gated incremental rebuilds.
WPF production app: scheduling, umbrella rebalancer, risk overlays, broker truth reconciliation, circuit breakers, deploy verification.
Gateway with automated session management, API health probes and graceful restart — hands-free connectivity around the clock.
Web-search-grounded LLM overlay reviews every final selection for disqualifying evidence — veto power only, never discretionary picks.
Not accepting investors. Open to research collaboration and partnership.
[email protected]Important Disclosure
Past performance is not indicative of future results. All performance data referenced is gross of fees. Live trading commenced in February 2026. The AUX series are internal sleeve designations, not registered funds
or exchange-traded products, and are not available for investment.